CN103648533B - 用于成像或治疗的包含反式环辛烯亲双烯体和二烯的预靶向试剂盒 - Google Patents

用于成像或治疗的包含反式环辛烯亲双烯体和二烯的预靶向试剂盒 Download PDF

Info

Publication number
CN103648533B
CN103648533B CN201280034134.4A CN201280034134A CN103648533B CN 103648533 B CN103648533 B CN 103648533B CN 201280034134 A CN201280034134 A CN 201280034134A CN 103648533 B CN103648533 B CN 103648533B
Authority
CN
China
Prior art keywords
targeting
probe
tco
effector
tetrazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280034134.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN103648533A (zh
Inventor
M.S.罗比拉德
J.卢布
R.罗斯辛
S.M.范登博世
R.M.维斯蒂根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tek Wolcos Pharmaceutical Co Ltd
Original Assignee
Koninklijke Philips Electronics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips Electronics NV filed Critical Koninklijke Philips Electronics NV
Publication of CN103648533A publication Critical patent/CN103648533A/zh
Application granted granted Critical
Publication of CN103648533B publication Critical patent/CN103648533B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CN201280034134.4A 2011-05-09 2012-05-07 用于成像或治疗的包含反式环辛烯亲双烯体和二烯的预靶向试剂盒 Expired - Fee Related CN103648533B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11165267A EP2522369A1 (en) 2011-05-09 2011-05-09 Pretargeting kit, method and agents used therein
EP11165267.3 2011-05-09
PCT/IB2012/052260 WO2012153254A1 (en) 2011-05-09 2012-05-07 Pretargeting kit for imaging or therapy comprising a trans - cyclooctene dienophile and a diene

Publications (2)

Publication Number Publication Date
CN103648533A CN103648533A (zh) 2014-03-19
CN103648533B true CN103648533B (zh) 2017-09-08

Family

ID=44484790

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280034134.4A Expired - Fee Related CN103648533B (zh) 2011-05-09 2012-05-07 用于成像或治疗的包含反式环辛烯亲双烯体和二烯的预靶向试剂盒

Country Status (7)

Country Link
US (1) US9913921B2 (enExample)
EP (2) EP2522369A1 (enExample)
JP (1) JP6223962B2 (enExample)
CN (1) CN103648533B (enExample)
AU (1) AU2012252024B2 (enExample)
CA (1) CA2835298C (enExample)
WO (1) WO2012153254A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6215194B2 (ja) 2011-05-16 2017-10-18 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 生体直交型薬物活性化
EP2948186A4 (en) * 2013-01-25 2016-10-05 Sloan Kettering Inst Cancer TETRAZINE / TRANSCYCLOOKTENE IN SOLID PHASE SYNTHESIS MARKED PEPTIDE
CN105611914B (zh) * 2013-06-19 2020-09-08 加利福尼亚大学董事会 局部递送治疗剂的化学构造物
US20160346409A1 (en) * 2014-02-10 2016-12-01 Mcmaster University Targeted molecular imaging contrast agents
CN106659796B (zh) * 2014-03-14 2021-04-30 加利福尼亚大学董事会 Tco缀合物和治疗剂递送方法
EP3125866B1 (en) * 2014-04-04 2021-03-03 President and Fellows of Harvard College Refillable drug delivery devices and methods of use thereof
US10179775B2 (en) 2014-08-11 2019-01-15 The General Hospital Corporation Cyclooctenes for bioorthogonol reactions
WO2016164565A1 (en) * 2015-04-08 2016-10-13 University Of Delaware Trans-cycloheptenes and hetero-trans-cycloheptenes for bioorthogonal coupling
WO2017031084A1 (en) 2015-08-14 2017-02-23 The Regents Of The University Of California Poly(vinyl alcohol) nanocarriers
CN117567535A (zh) 2015-09-10 2024-02-20 坦伯公司 生物正交组合物
US11690825B2 (en) 2016-03-09 2023-07-04 Board Of Regents, The University Of Texas System 20-HETE receptor (GPR75) antagonists and methods of use
WO2018004338A1 (en) 2016-06-27 2018-01-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
ES2983582T3 (es) 2017-04-07 2024-10-23 Tambo Inc Composiciones bioortogonales
US11560384B2 (en) 2017-05-04 2023-01-24 University Of Utah Research Foundation Benzonorbornadiene derivatives and reactions thereof
CN107746367B (zh) * 2017-11-07 2020-05-26 清华大学 β-石竹烯衍生物及其制备方法与应用
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
JP7554178B2 (ja) * 2018-07-26 2024-09-19 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド イメージングのための組成物および方法
EP3853234B1 (en) 2018-09-18 2025-04-23 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
CN119823023A (zh) 2018-10-10 2025-04-15 坦博公司 制备官能化环辛烯的工艺
IL289095A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Activating components to cleave labels from biomolecules in vivo
CN110954514B (zh) * 2019-12-02 2022-06-21 上海交通大学 适用于研究脂质体体内外分布的荧光示踪系统和方法
WO2022038183A1 (en) 2020-08-18 2022-02-24 Rigshospitalet Extracorporeal clearing traps based on inverse electron demand diels-alder cycloaddition for (pre)-targeted therapy and diagnostics
CA3239713A1 (en) * 2021-12-08 2023-06-15 Edward A. LEMKE Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
KR20250141267A (ko) * 2023-02-15 2025-09-26 태그웍스 파마슈티컬스 비.브이. 개선된 특성을 가지는 테트라진
CN118546131B (zh) * 2024-05-10 2025-02-28 四川大学华西医院 四嗪聚集诱导发光探针前体、探针及其制备方法、应用
CN119746111A (zh) * 2024-12-04 2025-04-04 苏州大学 一种体内放射性标记降低肝脏辐射剂量的试剂及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010119389A2 (en) * 2009-04-16 2010-10-21 Koninklijke Philips Electronics N.V. Pretargeting kit, method and agents used therein

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3143578A (en) * 1962-12-28 1964-08-04 Union Carbide Corp Preparation of tricyclo [8.2.1.02.9] trideca-5, 11-diene
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US5326856A (en) 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
US20030129191A1 (en) 1992-12-23 2003-07-10 Neorx Corporation Pretargeting methods and compounds
ATE391713T1 (de) * 2001-12-05 2008-04-15 California Inst Of Techn Enantioseletive umwandlung von alpha,beta- ungesättigten ketonen unter verwendung chiraler organischer katalysatoren
US8236949B2 (en) * 2007-07-17 2012-08-07 University Of Delaware Tetrazine-based bio-orthogonal coupling reagents and methods
EP2361098B1 (en) 2008-10-31 2019-08-28 The General Hospital Corporation Compositions and methods for delivering a substance to a biological target
RU2011146362A (ru) * 2009-04-16 2013-05-27 Конинклейке Филипс Электроникс Н.В. Набор для предварительного таргетинга, способ и средства, используемые в нем
EP2360167A1 (en) * 2010-02-03 2011-08-24 Deutsches Krebsforschungszentrum Post-synthetic modification of nucleic acids by inverse Diels-Alder reaction
EP2595967B1 (en) * 2010-07-23 2016-03-23 University Of Delaware Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes
JP6063384B2 (ja) * 2010-10-14 2017-01-18 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． プレターゲットキット、プレターゲット方法及びその使用試薬

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010119389A2 (en) * 2009-04-16 2010-10-21 Koninklijke Philips Electronics N.V. Pretargeting kit, method and agents used therein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DIELS ALDER REACTIONS OF CYCLOALKENONES IN ORGANIC SYNTHESIS;Francesco Fringuelli et al.;《ORGANIC PREPARATIONS AND PROCEDURES INT.》;19901231;第22卷(第2期);第131-165页 *

Also Published As

Publication number Publication date
US20140093450A1 (en) 2014-04-03
EP2707035B1 (en) 2020-04-01
US9913921B2 (en) 2018-03-13
EP2522369A1 (en) 2012-11-14
AU2012252024B2 (en) 2017-06-29
EP2707035A1 (en) 2014-03-19
JP2014518861A (ja) 2014-08-07
CA2835298C (en) 2019-06-18
WO2012153254A1 (en) 2012-11-15
CN103648533A (zh) 2014-03-19
JP6223962B2 (ja) 2017-11-01
CA2835298A1 (en) 2012-11-15
AU2012252024A1 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
CN103648533B (zh) 用于成像或治疗的包含反式环辛烯亲双烯体和二烯的预靶向试剂盒
JP6368745B2 (ja) プレターゲットキット、プレターゲット方法及びその使用試薬
CN103328008B (zh) 用于从循环清除生物分子的试剂
CN102395380B (zh) 预靶向试剂盒、方法和其中使用的试剂
CN102438656B (zh) 预靶向试剂盒、方法和其中使用的试剂
JP2014506869A5 (enExample)
JP7784899B2 (ja) 高速で且つ効率的なクリック放出の為の化合物
JP2014500307A5 (enExample)
JP2014515040A (ja) 生体直交型薬物活性化
CN111263747A (zh) 双官能螯合物的药代动力学增强及其用途
CA3143924A1 (en) Agents for cleaving labels from biomolecules in vivo
CN103269721B (zh) 预靶向试剂盒、方法和其中使用的试剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20180307

Address after: Eindhoven

Patentee after: Tek wolcos Pharmaceutical Co., Ltd.

Address before: Holland Ian Deho Finn

Patentee before: Koninkl Philips Electronics NV

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170908

Termination date: 20180507